Entrada Therapeutics Inc (TRDA)
19.40
+0.60
(+3.19%)
USD |
NASDAQ |
Nov 25, 13:18
Entrada Therapeutics Net Income (Quarterly): -14.03M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -14.03M |
June 30, 2024 | 55.03M |
March 31, 2024 | 23.50M |
December 31, 2023 | -9.544M |
September 30, 2023 | 35.46M |
June 30, 2023 | -25.93M |
March 31, 2023 | -6.674M |
December 31, 2022 | -24.63M |
September 30, 2022 | -25.14M |
Date | Value |
---|---|
June 30, 2022 | -23.18M |
March 31, 2022 | -21.67M |
December 31, 2021 | -18.45M |
September 30, 2021 | -14.43M |
June 30, 2021 | -9.901M |
March 31, 2021 | -8.38M |
December 31, 2020 | -8.673M |
September 30, 2020 | -6.99M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-25.93M
Minimum
Jun 2023
55.03M
Maximum
Jun 2024
-6.096M
Average
-9.901M
Median
Jun 2021
Net Income (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | 43.88M |
Vertex Pharmaceuticals Inc | 1.045B |
Assembly Biosciences Inc | -9.613M |
Sarepta Therapeutics Inc | 33.61M |
Regenxbio Inc | -59.60M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 19.57M |
Total Expenses (Quarterly) | 41.23M |
EPS Diluted (Quarterly) | -0.35 |
Enterprise Value | 254.15M |
Profit Margin (Quarterly) | -71.70% |
Earnings Yield | 8.20% |
Operating Earnings Yield | 8.26% |
Normalized Earnings Yield | 8.196 |